Listed

Cardiff Oncology, Inc.

CRDFNasdaqCIK 1213037HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$104.0k, Q2 FY2026
Operating income−$9.6m, Q2 FY2026
Net income−$9.2m, Q2 FY2026
Cardiff Oncology, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m0.1Revenue, Q3 FY2023, three months to 2023-09-30$141.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-07, accession 0000950170-24-123242.Report this figure0.2Revenue, Q4 FY2023, three months to 2023-12-31$156.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-27, accession 0000950170-25-028992. Derived: 12-month figure less the 9-month figure.Report this figure0.2Revenue, Q1 FY2024, three months to 2024-03-31$205.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-08, accession 0000950170-25-066886.Report this figure0.2Revenue, Q2 FY2024, three months to 2024-06-30$163.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-07-29, accession 0000950170-25-099610.Report this figure0.2Revenue, Q3 FY2024, three months to 2024-09-30$165.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001193125-25-269424.Report this figure0.2Revenue, Q4 FY2024, three months to 2024-12-31$151.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001193125-26-067464. Derived: 12-month figure less the 9-month figure.Report this figure0.1Revenue, Q1 FY2025, three months to 2025-03-31$109.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001213037-26-000011.Report this figure0.1Revenue, Q2 FY2025, three months to 2025-06-30$121.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure0.1Revenue, Q3 FY2025, three months to 2025-09-30$120.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001193125-25-269424.Report this figure0.2Revenue, Q4 FY2025, three months to 2025-12-31$243.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-24, accession 0001193125-26-067464. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2026, three months to 2026-03-31$41.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001213037-26-000011.Report this figure0.1Revenue, Q2 FY2026, three months to 2026-06-30$104.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure
Cost of revenue$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Selling, general and administrative$m2.9Selling, general and administrative, Q3 FY2023, three months to 2023-09-30$2.9m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2024-11-07, accession 0000950170-24-123242.Report this figure2.7Selling, general and administrative, Q4 FY2023, three months to 2023-12-31$2.7m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2025-02-27, accession 0000950170-25-028992. Derived: 12-month figure less the 9-month figure.Report this figure3.1Selling, general and administrative, Q1 FY2024, three months to 2024-03-31$3.1m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-05-08, accession 0000950170-25-066886.Report this figure3.2Selling, general and administrative, Q2 FY2024, three months to 2024-06-30$3.2m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-07-29, accession 0000950170-25-099610.Report this figure3.1Selling, general and administrative, Q3 FY2024, three months to 2024-09-30$3.1m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-11-06, accession 0001193125-25-269424.Report this figure3.0Selling, general and administrative, Q4 FY2024, three months to 2024-12-31$3.0m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-02-24, accession 0001193125-26-067464. Derived: 12-month figure less the 9-month figure.Report this figure4.0Selling, general and administrative, Q1 FY2025, three months to 2025-03-31$4.0m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-05-14, accession 0001213037-26-000011.Report this figure3.3Selling, general and administrative, Q2 FY2025, three months to 2025-06-30$3.3m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure3.9Selling, general and administrative, Q3 FY2025, three months to 2025-09-30$3.9m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-11-06, accession 0001193125-25-269424.Report this figure3.0Selling, general and administrative, Q4 FY2025, three months to 2025-12-31$3.0m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-02-24, accession 0001193125-26-067464. Derived: 12-month figure less the 9-month figure.Report this figure6.1Selling, general and administrative, Q1 FY2026, three months to 2026-03-31$6.1m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-05-14, accession 0001213037-26-000011.Report this figure3.8Selling, general and administrative, Q2 FY2026, three months to 2026-06-30$3.8m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure
Operating income$m(10.8)Operating income, Q3 FY2023, three months to 2023-09-30−$10.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-07, accession 0000950170-24-123242.Report this figure(10.3)Operating income, Q4 FY2023, three months to 2023-12-31−$10.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-27, accession 0000950170-25-028992. Derived: 12-month figure less the 9-month figure.Report this figure(10.9)Operating income, Q1 FY2024, three months to 2024-03-31−$10.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-08, accession 0000950170-25-066886.Report this figure(12.5)Operating income, Q2 FY2024, three months to 2024-06-30−$12.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-07-29, accession 0000950170-25-099610.Report this figure(12.6)Operating income, Q3 FY2024, three months to 2024-09-30−$12.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269424.Report this figure(12.6)Operating income, Q4 FY2024, three months to 2024-12-31−$12.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-24, accession 0001193125-26-067464. Derived: 12-month figure less the 9-month figure.Report this figure(14.4)Operating income, Q1 FY2025, three months to 2025-03-31−$14.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001213037-26-000011.Report this figure(14.8)Operating income, Q2 FY2025, three months to 2025-06-30−$14.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure(12.0)Operating income, Q3 FY2025, three months to 2025-09-30−$12.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269424.Report this figure(7.8)Operating income, Q4 FY2025, three months to 2025-12-31−$7.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-24, accession 0001193125-26-067464. Derived: 12-month figure less the 9-month figure.Report this figure(12.9)Operating income, Q1 FY2026, three months to 2026-03-31−$12.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001213037-26-000011.Report this figure(9.6)Operating income, Q2 FY2026, three months to 2026-06-30−$9.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure
Interest expense$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$m(9.7)Net income, Q3 FY2023, three months to 2023-09-30−$9.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-07, accession 0000950170-24-123242.Report this figure(9.3)Net income, Q4 FY2023, three months to 2023-12-31−$9.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-27, accession 0000950170-25-028992. Derived: 12-month figure less the 9-month figure.Report this figure(10.0)Net income, Q1 FY2024, three months to 2024-03-31−$10.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269424.Report this figure(11.8)Net income, Q2 FY2024, three months to 2024-06-30−$11.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269424.Report this figure(11.9)Net income, Q3 FY2024, three months to 2024-09-30−$11.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269424.Report this figure(11.8)Net income, Q4 FY2024, three months to 2024-12-31−$11.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-24, accession 0001193125-26-067464. Derived: 12-month figure less the 9-month figure.Report this figure(13.4)Net income, Q1 FY2025, three months to 2025-03-31−$13.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure(13.9)Net income, Q2 FY2025, three months to 2025-06-30−$13.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure(11.3)Net income, Q3 FY2025, three months to 2025-09-30−$11.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269424.Report this figure(7.2)Net income, Q4 FY2025, three months to 2025-12-31−$7.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-24, accession 0001193125-26-067464. Derived: 12-month figure less the 9-month figure.Report this figure(12.3)Net income, Q1 FY2026, three months to 2026-03-31−$12.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure(9.2)Net income, Q2 FY2026, three months to 2026-06-30−$9.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure
Diluted EPS$ per share(0.22)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-07, accession 0000950170-24-123242.Report this figurenot reported(0.22)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-08, accession 0000950170-25-066886.Report this figure(0.26)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.26 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-07-29, accession 0000950170-25-099610.Report this figure(0.25)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001193125-25-269424.Report this figurenot reported(0.20)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001213037-26-000011.Report this figure(0.21)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.21 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure(0.17)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.17 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001193125-25-269424.Report this figurenot reported(0.18)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.18 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001213037-26-000011.Report this figure(0.14)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure
Basic EPS$ per share(0.22)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.22 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-07, accession 0000950170-24-123242.Report this figurenot reported(0.22)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.22 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-08, accession 0000950170-25-066886.Report this figure(0.26)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.26 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-07-29, accession 0000950170-25-099610.Report this figure(0.25)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.25 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001193125-25-269424.Report this figurenot reported(0.20)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.20 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-14, accession 0001213037-26-000011.Report this figure(0.21)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.21 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure(0.17)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.17 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001193125-25-269424.Report this figurenot reported(0.18)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.18 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-14, accession 0001213037-26-000011.Report this figure(0.14)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.14 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure

Balance sheet

Cash and equivalents$9.2m, Q2 FY2026
Shareholders' equity$26.5m, Q2 FY2026
Cardiff Oncology, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m15.2Cash and equivalents, Q3 FY2023, at 2023-09-30$15.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-02, accession 0001628280-23-036375.Report this figure21.7Cash and equivalents, FY2023, at 2023-12-31$21.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-02-27, accession 0000950170-25-028992.Report this figure18.7Cash and equivalents, Q1 FY2024, at 2024-03-31$18.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-02, accession 0001628280-24-019974.Report this figure25.5Cash and equivalents, Q2 FY2024, at 2024-06-30$25.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-08, accession 0001628280-24-036098.Report this figure13.0Cash and equivalents, Q3 FY2024, at 2024-09-30$13.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-07, accession 0000950170-24-123242.Report this figure51.5Cash and equivalents, FY2024, at 2024-12-31$51.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-24, accession 0001193125-26-067464.Report this figure24.1Cash and equivalents, Q1 FY2025, at 2025-03-31$24.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-08, accession 0000950170-25-066886.Report this figure10.8Cash and equivalents, Q2 FY2025, at 2025-06-30$10.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-07-29, accession 0000950170-25-099610.Report this figure10.1Cash and equivalents, Q3 FY2025, at 2025-09-30$10.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001193125-25-269424.Report this figure17.5Cash and equivalents, FY2025, at 2025-12-31$17.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure8.5Cash and equivalents, Q1 FY2026, at 2026-03-31$8.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-14, accession 0001213037-26-000011.Report this figure9.2Cash and equivalents, Q2 FY2026, at 2026-06-30$9.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure
Current assets$m83.9Current assets, Q3 FY2023, at 2023-09-30$83.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-02, accession 0001628280-23-036375.Report this figure77.4Current assets, FY2023, at 2023-12-31$77.4m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-27, accession 0000950170-25-028992.Report this figure70.0Current assets, Q1 FY2024, at 2024-03-31$70.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-02, accession 0001628280-24-019974.Report this figure62.2Current assets, Q2 FY2024, at 2024-06-30$62.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-08, accession 0001628280-24-036098.Report this figure59.3Current assets, Q3 FY2024, at 2024-09-30$59.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-07, accession 0000950170-24-123242.Report this figure95.1Current assets, FY2024, at 2024-12-31$95.1m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-24, accession 0001193125-26-067464.Report this figure82.7Current assets, Q1 FY2025, at 2025-03-31$82.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-08, accession 0000950170-25-066886.Report this figure73.7Current assets, Q2 FY2025, at 2025-06-30$73.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-07-29, accession 0000950170-25-099610.Report this figure61.8Current assets, Q3 FY2025, at 2025-09-30$61.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-06, accession 0001193125-25-269424.Report this figure60.1Current assets, FY2025, at 2025-12-31$60.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure47.3Current assets, Q1 FY2026, at 2026-03-31$47.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-14, accession 0001213037-26-000011.Report this figure35.6Current assets, Q2 FY2026, at 2026-06-30$35.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure
Total assets$m88.5Total assets, Q3 FY2023, at 2023-09-30$88.5m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-02, accession 0001628280-23-036375.Report this figure81.6Total assets, FY2023, at 2023-12-31$81.6m. XBRL concept us-gaap:Assets. 10-K filed 2025-02-27, accession 0000950170-25-028992.Report this figure74.0Total assets, Q1 FY2024, at 2024-03-31$74.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-02, accession 0001628280-24-019974.Report this figure66.1Total assets, Q2 FY2024, at 2024-06-30$66.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-08, accession 0001628280-24-036098.Report this figure62.9Total assets, Q3 FY2024, at 2024-09-30$62.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-07, accession 0000950170-24-123242.Report this figure97.2Total assets, FY2024, at 2024-12-31$97.2m. XBRL concept us-gaap:Assets. 10-K filed 2026-02-24, accession 0001193125-26-067464.Report this figure84.8Total assets, Q1 FY2025, at 2025-03-31$84.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-08, accession 0000950170-25-066886.Report this figure75.7Total assets, Q2 FY2025, at 2025-06-30$75.7m. XBRL concept us-gaap:Assets. 10-Q filed 2025-07-29, accession 0000950170-25-099610.Report this figure63.8Total assets, Q3 FY2025, at 2025-09-30$63.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-06, accession 0001193125-25-269424.Report this figure61.9Total assets, FY2025, at 2025-12-31$61.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure49.2Total assets, Q1 FY2026, at 2026-03-31$49.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-14, accession 0001213037-26-000011.Report this figure37.3Total assets, Q2 FY2026, at 2026-06-30$37.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure
Current liabilities$m9.0Current liabilities, Q3 FY2023, at 2023-09-30$9.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-02, accession 0001628280-23-036375.Report this figure10.4Current liabilities, FY2023, at 2023-12-31$10.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-27, accession 0000950170-25-028992.Report this figure11.8Current liabilities, Q1 FY2024, at 2024-03-31$11.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-02, accession 0001628280-24-019974.Report this figure12.5Current liabilities, Q2 FY2024, at 2024-06-30$12.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-08, accession 0001628280-24-036098.Report this figure12.5Current liabilities, Q3 FY2024, at 2024-09-30$12.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-07, accession 0000950170-24-123242.Report this figure13.4Current liabilities, FY2024, at 2024-12-31$13.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-24, accession 0001193125-26-067464.Report this figure13.3Current liabilities, Q1 FY2025, at 2025-03-31$13.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-08, accession 0000950170-25-066886.Report this figure16.7Current liabilities, Q2 FY2025, at 2025-06-30$16.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-07-29, accession 0000950170-25-099610.Report this figure14.7Current liabilities, Q3 FY2025, at 2025-09-30$14.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-06, accession 0001193125-25-269424.Report this figure16.4Current liabilities, FY2025, at 2025-12-31$16.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure14.5Current liabilities, Q1 FY2026, at 2026-03-31$14.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-14, accession 0001213037-26-000011.Report this figure10.8Current liabilities, Q2 FY2026, at 2026-06-30$10.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure
Total liabilities$m10.6Total liabilities, Q3 FY2023, at 2023-09-30$10.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-02, accession 0001628280-23-036375.Report this figure11.9Total liabilities, FY2023, at 2023-12-31$11.9m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-27, accession 0000950170-25-028992.Report this figure13.1Total liabilities, Q1 FY2024, at 2024-03-31$13.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-02, accession 0001628280-24-019974.Report this figure13.7Total liabilities, Q2 FY2024, at 2024-06-30$13.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-08, accession 0001628280-24-036098.Report this figure13.5Total liabilities, Q3 FY2024, at 2024-09-30$13.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-07, accession 0000950170-24-123242.Report this figure14.2Total liabilities, FY2024, at 2024-12-31$14.2m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-24, accession 0001193125-26-067464.Report this figure13.9Total liabilities, Q1 FY2025, at 2025-03-31$13.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-08, accession 0000950170-25-066886.Report this figure17.1Total liabilities, Q2 FY2025, at 2025-06-30$17.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-07-29, accession 0000950170-25-099610.Report this figure15.0Total liabilities, Q3 FY2025, at 2025-09-30$15.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-06, accession 0001193125-25-269424.Report this figure16.5Total liabilities, FY2025, at 2025-12-31$16.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure14.5Total liabilities, Q1 FY2026, at 2026-03-31$14.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-14, accession 0001213037-26-000011.Report this figure10.8Total liabilities, Q2 FY2026, at 2026-06-30$10.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure
Short-term borrowings$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m77.8Shareholders' equity, Q3 FY2023, at 2023-09-30$77.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-07, accession 0000950170-24-123242.Report this figure69.7Shareholders' equity, FY2023, at 2023-12-31$69.7m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-02-24, accession 0001193125-26-067464.Report this figure60.9Shareholders' equity, Q1 FY2024, at 2024-03-31$60.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269424.Report this figure52.4Shareholders' equity, Q2 FY2024, at 2024-06-30$52.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269424.Report this figure49.4Shareholders' equity, Q3 FY2024, at 2024-09-30$49.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269424.Report this figure82.9Shareholders' equity, FY2024, at 2024-12-31$82.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure70.9Shareholders' equity, Q1 FY2025, at 2025-03-31$70.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure58.6Shareholders' equity, Q2 FY2025, at 2025-06-30$58.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure48.8Shareholders' equity, Q3 FY2025, at 2025-09-30$48.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269424.Report this figure45.4Shareholders' equity, FY2025, at 2025-12-31$45.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure34.7Shareholders' equity, Q1 FY2026, at 2026-03-31$34.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure26.5Shareholders' equity, Q2 FY2026, at 2026-06-30$26.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure

Cash flow

Operating cash flow−$11.8m, Q2 FY2026
Capital expenditure$0, Q4 FY2025
Cardiff Oncology, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(8.0)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$8.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-07, accession 0000950170-24-123242. Derived: 9-month figure less the 6-month figure.Report this figure(7.1)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$7.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-27, accession 0000950170-25-028992. Derived: 12-month figure less the 9-month figure.Report this figure(7.7)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$7.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-08, accession 0000950170-25-066886.Report this figure(9.2)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$9.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-07-29, accession 0000950170-25-099610. Derived: 6-month figure less the 3-month figure.Report this figure(10.5)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$10.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001193125-25-269424. Derived: 9-month figure less the 6-month figure.Report this figure(10.3)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$10.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-24, accession 0001193125-26-067464. Derived: 12-month figure less the 9-month figure.Report this figure(12.8)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$12.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001213037-26-000011.Report this figure(8.3)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$8.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001193125-26-344545. Derived: 6-month figure less the 3-month figure.Report this figure(10.8)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$10.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001193125-25-269424. Derived: 9-month figure less the 6-month figure.Report this figure(6.0)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$6.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-24, accession 0001193125-26-067464. Derived: 12-month figure less the 9-month figure.Report this figure(12.3)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$12.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001213037-26-000011.Report this figure(11.8)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$11.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001193125-26-344545. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.3Capital expenditure, Q3 FY2023, three months to 2023-09-30$315.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-07, accession 0000950170-24-123242. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$8.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-27, accession 0000950170-25-028992. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2024, three months to 2024-03-31$80.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-08, accession 0000950170-25-066886.Report this figure0.0Capital expenditure, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-07-29, accession 0000950170-25-099610. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001193125-25-269424. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-24, accession 0001193125-26-067464. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported0.0Capital expenditure, Q3 FY2025, three months to 2025-09-30$18.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001193125-25-269424. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-24, accession 0001193125-26-067464. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported

Shares

Diluted shares (weighted)68.40m, Q2 FY2026
Cardiff Oncology, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares43.3Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3043,333,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-02, accession 0001628280-23-036375.Report this figure44.7Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3144,677,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-02, accession 0001628280-24-019974.Report this figure44.7Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3044,677,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-08, accession 0001628280-24-036098.Report this figure44.7Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3044,677,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-07, accession 0000950170-24-123242.Report this figure44.7Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3144,678,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-08, accession 0000950170-25-066886.Report this figure44.8Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3044,825,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-07-29, accession 0000950170-25-099610.Report this figure46.9Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3046,865,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001193125-25-269424.Report this figure66.5Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3166,524,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-14, accession 0001213037-26-000011.Report this figure66.5Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3066,526,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure66.9Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3066,879,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001193125-25-269424.Report this figure68.4Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3168,350,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-14, accession 0001213037-26-000011.Report this figure68.4Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3068,397,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure

Shares outstanding: 77.80mShares outstanding, period not labelled, at 2026-08-0677,795,249 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-344545.Report this figure at Aug 6, 2026, from the cover of the 10-Q filed Aug 11, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. Listed shows no prices and gives no investment advice.